Some results of a pilot study of mutations in ASXL1 and DNMT3A genes in myelodysplastic syndrome
https://doi.org/10.21886/2712-8156-2023-4-1-97-105
Abstract
Оbjective: was to determine the prevalence of the c.1934dupG mutation in the ASXL1 gene and the R882H mutation in the DNMT3A gene in MDS and their influence on significant clinical characteristics. Materials and methods: 33 men and 17 women with a median age of 57 years (18 –83) and a verified diagnosis of myelodysplastic syndrome were included in the study. Twenty-two volunteers without hematologic pathology were taken as controls, of them: 8 men and 14 women aged from 22 to 65 years. PCR examination of venous blood was performed in all study groups to detect c.1934dupG and R882H with Sanger reference sequencing. Results: the R882H mutation was not detected in any of the study groups. The c.1934dupG mutation was not detected in individuals without hematologic pathology. Due to a lack of concentration of isolated DNA from venous blood cells, no analysis of amplification efficiency could be performed in 7 patients. The c.1934dupG mutation was found in 46% of patients and was found in all IPSS-R, WPSS, and MDS-CI risk groups. No differences were found in the analysis of survival in the presence and absence of the c.1934dupG mutation. Conclusions: the study demonstrated that the developed method for the detection of the c.1934dupG mutation in venous blood cells enables optimization of diagnosis. A limitation of the adapted amplification and restriction assays was the degree of blood leucopenia. No effect of the c.1934dupG mutation on the clinical course of myelodysplastic syndrome was detected.
About the Authors
P. V. Lipilkin
Rostov State Medical University; Don State Technical University
Russian Federation
Russian Federation
Pavel V. Lipilkin, senior lecturer of the Department of Biology and general pathology
Rostov-on-Don
E. D. Kulaeva
Southern Federal University
Elizaveta D. Kulaeva, research assistant, Department of Genetics, Biology of development and genome organisation laboratory, Research Institute of Biology
Rostov-on-Don
E. V. Ryabikina
Rostov State Medical University
Elena V. Ryabikina, assistant professor of the Department of Hematology and Transfusiology with a Сourse of Сlinical Laboratory Diagnostics, Genetics and Laboratory Genetics
Rostov-on-Don
E. V. Degtereva
Rostov State Medical University
Elena V. Degtereva, assistant professor of the Department of Hematology and Transfusiology with a Сourse of Сlinical Laboratory Diagnostics, Genetics and Laboratory Genetics
Rostov-on-Don
Yu. V. Shatokhin
Rostov State Medical University
Yuri V. Shatokhin, MD, professor of the Department of Hematology and Transfusiology with courses in clinical laboratory diagnostics, genetics and laboratory genetics
Rostov-on-Don
References
1. Pati H, Kundil Veetil K. Myelodysplastic Syndrome/ Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications. Indian J Hematol Blood Transfus. 2019;35(1):3-11. doi: 10.1007/s12288-019-01084-y
2. Heuser M, Yun H, Thol F. Epigenetics in myelodysplastic syndromes. Semin Cancer Biol. 2018;51:170-179. doi: 10.1016/j.semcancer.2017.07.009
3. Ganguly BB, Kadam NN. Mutations of myelodysplastic syndromes (MDS): An update. Mutat Res Rev Mutat Res. 2016;769:47-62. doi: 10.1016/j.mrrev.2016.04.009
4. Lin Y, Zheng Y, Wang ZC, Wang SY. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis. Hematology. 2016;21(8):454-461. doi: 10.1080/10245332.2015.1106815
5. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12. doi: 10.1186/1756-8722-5-12
6. Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer. 2013;109(2):299-306. doi: 10.1038/ bjc.2013.281
7. Montes-Moreno S, Routbort MJ, Lohman EJ, Barkoh BA, Kanagal-Shamanna R, Bueso-Ramos CE, et al. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS One. 2018;13(9):e0204218. doi: 10.1371/journal.pone.0204218
8. Wang L, Birch NW, Zhao Z, Nestler CM, Kazmer A, Shilati A, et al. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. Nat Cancer. 2021;2(5):515-526. doi: 10.1038/s43018-021-00199-4
9. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153-1158. doi: 10.1038/ leu.2011.44
10. Xu F, Wu LY, He Q, Wu D, Zhang Z, Song LX, et al. Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Sci Rep. 2017;7:43113. doi: 10.1038/srep43113
11. Xu Y, Li Y, Xu Q, Chen Y, Lv N, Jing Y, et al. Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing. Oncotarget. 2017;8(47):82475-82490. doi: 10.18632/oncotarget.19628
12. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454- 2465. doi: 10.1182/blood-2012-03-420489
13. Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96(10):1433- 1440. doi: 10.3324/haematol.2011.044602
14. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011; 96(3):441- 9. doi: 10.3324/haematol.2010.033506
Review
For citations:
Lipilkin P.V., Kulaeva E.D., Ryabikina E.V., Degtereva E.V., Shatokhin Yu.V. Some results of a pilot study of mutations in ASXL1 and DNMT3A genes in myelodysplastic syndrome. South Russian Journal of Therapeutic Practice. 2023;4(1):97-105. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-1-97-105
Views:
529
Email this article 